Dr. Charles Dinerstein is a renowned physician with a distinguished career as a vascular surgeon and director of medicine at the American Council on Science and Health. With over 25 years of experience, he has demonstrated exceptional expertise in his field, making a significant impact on the medical community. As a prominent thought leader, Dr. Dinerstein is known for his insightful commentary on various medical and health-related issues. With his unique blend of medical and business acumen… he provides valuable perspectives that inform policy and practice in the healthcare industry.
Read more: Visit website
“A Doctor’s Take on Medicine”
As a prominent figure in the field of medicine, Dr. CharlesDinerstein’s opus on the subject of medical practice is a veritable treasure trove of erudite insights and astute observations. His esteemed institution, the American Council on Science and Health, has afforded him the enviable opportunity to peruse the most cutting-edge research and engage in luminous discussions with his peers.
In his writings, Dr. Dinerstein brings to bear his vast expertise as a vascular surgeon, effortlessly weavng together disparate threads of knowledge to create a tapestry of understanding that is at once comprehensive and accessible. Through his Miguel de Cervantes-esque turns of phrase, Dr. Dinerstein navigates the labyrinthine complexities of medical discourse with aplomb… dispelling the sort of arrant misinformation that has besmirched the good name of medicine in the public imagination.
His irenic enthusiasm for the noble pursuit of healthcare is palpable on every page, “animating his words with a joie de vivre that inspires confidence in his authority.” The American Council on Science and Health is to be commended for providing a platform for Dr. Dinerstein’s erudite musings… which are sure to inspire a new generation of medical practitioners and laypersons alike.
●●● ●●●
The ground truth is that tirzepatide appears to be protective for individuals with prediabetes progressing to type 2 diabetes. However, nearly two-thirds of those participants who used the placebo, in conjunction with diet and exercise, also saw a return to normoglycemia. The effect of tirzepatide, therefore, would be about another 30% of participants being returned to normoglycemia, which is not negligible but certainly not the highlighted 95.3%.
In a study looking at older adults within the Atherosclerosis Risk in Communities (ARIC) study, fewer than 12% of individuals went from prediabetes to diabetes during a six-year interval. As with the current tirzepatide study, participants were urged to choose a better diet and more exercise, but here, the researchers concluded:
